IFM Investors Pty Ltd Has $25.67 Million Stock Holdings in Medtronic PLC $MDT

IFM Investors Pty Ltd lifted its position in shares of Medtronic PLC (NYSE:MDT) by 4.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 296,199 shares of the medical technology company’s stock after purchasing an additional 12,117 shares during the period. IFM Investors Pty Ltd’s holdings in Medtronic were worth $25,666,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in MDT. Lodestone Wealth Management LLC acquired a new position in Medtronic in the 4th quarter valued at approximately $27,000. Anfield Capital Management LLC raised its stake in shares of Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 230 shares during the last quarter. Monetary Solutions Ltd acquired a new position in shares of Medtronic during the fourth quarter worth $27,000. Board of the Pension Protection Fund acquired a new position in shares of Medtronic during the fourth quarter worth $29,000. Finally, GoalVest Advisory LLC bought a new stake in shares of Medtronic in the fourth quarter worth $29,000. Institutional investors own 82.06% of the company’s stock.

Medtronic Price Performance

MDT stock opened at $78.25 on Wednesday. The company has a quick ratio of 1.62, a current ratio of 2.13 and a debt-to-equity ratio of 0.52. The firm has a market cap of $100.17 billion, a price-to-earnings ratio of 20.98, a PEG ratio of 2.17 and a beta of 0.58. The company’s fifty day simple moving average is $79.14 and its 200 day simple moving average is $89.37. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The firm had revenue of $9.81 billion during the quarter, compared to the consensus estimate of $9.62 billion. During the same period last year, the business posted $1.62 EPS. The business’s revenue was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, analysts expect that Medtronic PLC will post 5.94 earnings per share for the current year.

Medtronic Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 17th. Shareholders of record on Friday, June 26th will be issued a $0.72 dividend. The ex-dividend date is Friday, June 26th. This is an increase from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a yield of 3.7%. Medtronic’s dividend payout ratio is presently 77.21%.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.26% of the company’s stock.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Some recent commentary argues Medtronic looks undervalued after its pullback, with bullish write-ups pointing to attractive valuation metrics and the company’s defensive healthcare profile as reasons the stock could offer upside from current levels. Article Title
• Positive Sentiment: Medtronic has also been highlighted by some investors as a long-term holding, helped by the company’s recent FDA 510(k) clearance for its Nellcor pulse oximetry system, which could support its product pipeline and reinforce confidence in future innovation. Article Title
• Positive Sentiment: Several bullish opinion pieces published over the past two days framed MDT as a potentially appealing buy for income and value-oriented investors, which may be helping offset some of the weakness from broader market sentiment. Article Title
• Neutral Sentiment: Other coverage focused on how Medtronic compares with peers like Globus Medical, with analysts suggesting Medtronic may have less upside than faster-growing rivals. That comparison could weigh on sentiment, but it was more of a relative valuation discussion than a direct company-specific setback. Article Title
• Negative Sentiment: Despite the bullish commentary, the stock has been trending lower recently, and a market recap noted MDT’s shares fell while the broader market gained, reinforcing concerns that investors may still be cautious about near-term growth and momentum. Article Title

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on MDT. Leerink Partners decreased their price objective on Medtronic from $117.00 to $104.00 and set an “outperform” rating for the company in a report on Thursday, June 4th. The Goldman Sachs Group reduced their price target on Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a research report on Thursday, June 4th. Argus decreased their price target on Medtronic from $125.00 to $115.00 and set a “buy” rating for the company in a research note on Monday, April 6th. JPMorgan Chase & Co. decreased their price target on Medtronic from $100.00 to $86.00 and set a “neutral” rating for the company in a research note on Thursday, June 4th. Finally, TD Cowen restated a “buy” rating and set a $119.00 price objective on shares of Medtronic in a research report on Thursday, June 4th. Seventeen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $99.00.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).